In this video, Tiziano Barbui, MD, Bergamo Hospital Research Foundation, Bergamo, Italy, gives a detailed overview of the European LeukemiaNet's updated guidelines for the treatment and management of polycythemia vera (PV). Prof. Barbui shares some insights into how patients with PV are divided into high- and low-risk categories based on age and history of thrombosis, and further discusses the role of hydroxyurea in the treatment of PV. The recent approval of ropeginterferon alfa-2b has also impacted the treatment landscape of this disease, and Prof. Barbui further comments on this, as well as the use of cytoreductive therapy versus phlebotomy in patients. also by This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
